Hemp Archives - Page 2 of 9 - InvestorWire (IW)

Friday May 10, 2024 - 2:35 pm

InvestorNewsBreaks – CannaCon West to Propel Growth of Cannabis Industry in Western US

CannaCon, a leading conference company, is announcing the CannaCon West Albuquerque. The event is set to take place on May 17-18, 2024, at the stunning Albuquerque Convention Center, Albuquerque. CannaCon West Albuquerque is one of several national CannaCon expos. It is designed to propel the growth of the cannabis industry in the western U.S., reverberate nationally, and create lasting value for years to come. According…

Thursday May 09, 2024 - 3:35 pm

InvestorNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Filling Void in Hemp and Cannabis Market

Astrotech (NASDAQ: ASTC), a science and technology development and commercialization company, and its wholly owned subsidiary, AgLAB Inc., have developed a mass spectrometer designed for use in the hemp and cannabis market. “During the process of converting cannabis biomass into distillate, valuable cannabinoids are typically lost, resulting in reduced profits. AgLAB’s Maximum Value Processing (‘MVP’) method uses the powerful AgLAB-1000-D2 mass spectrometer to test and…

Wednesday May 01, 2024 - 12:42 pm

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Responds to Reported Plans for DEA to Reschedule Cannabis

Flora Growth (NASDAQ: FLGC), a cannabis-focused consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000-plus points of distribution around the world, is responding to the reported historic move by the U.S. Drug Enforcement Administration ("DEA") to reclassify cannabis from its list of Schedule I drugs to Schedule III. According to the announcement, Flora Growth applauds the move, which is…

Tuesday Apr 30, 2024 - 9:26 am

InvestorNewsBreaks — Red White & Bloom Brands Inc. (CSE: RWB) (OTC: RWBYF) Files Documents Reporting Financial Results for Q4, FY 2023

Red White & Bloom (CSE: RWB) (OTC: RWBYF), a multistate cannabis operator and house of premium brands, has filed key required documents for fiscal year 2023. Included among the documents filed are RWB’s Consolidated Audited Financial Statements, Management's Discussion and Analysis, and other related certifications. The documents show the company’s financial results for fourth-quarter 2023 and fiscal year 2023. According to the documents, the company’s…

Thursday Apr 25, 2024 - 9:31 am

InvestorNewsBreaks – Golden Triangle Ventures Inc. (GTVH), Subsidiary Establish Four-Pillar Business Model to Ensure Successful Development of Destino Ranch

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, and its wholly owned subsidiary, Lavish Entertainment (or “Lavish”), have developed a comprehensive four-pillar business model. According to the announcement, the company intends for this key business component to be a critical component moving forward as Lavish Entertainment focuses on creating an industry-leading entertainment business. Specifically, the business model will be used as the company’s flagship…

Tuesday Apr 23, 2024 - 3:10 pm

InvestorNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Making Significant Strides to Create Premier Entertainment Destination

Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment, have made significant progress in transforming into reality the vision for a premier destination for year-round, world-class music, entertainment and art. “Since the announcement of Destino Ranch, a planned 638-acre property conveniently located within a short drive from large population centers such as Phoenix, Los Angeles and Las Vegas, Lavish Entertainment has officially activated…

Tuesday Apr 23, 2024 - 10:55 am

InvestorNewsBreaks – Zoned Properties Inc. (ZDPY) Announces $1M Stock Repurchase Program

Zoned Properties (OTCQB: ZDPY), a leading real estate development firm for emerging and highly regulated industries including legalized cannabis, today announced that its board of directors has approved a share repurchase program, pursuant to which the company is authorized to purchase up to $1 million of its common stock over an unlimited time period. “As our business continues to outperform in a challenging overall operating…

Thursday Apr 11, 2024 - 9:40 am

InvestorNewsBreaks – Golden Triangle Ventures Inc. (GTVH), Lavish Entertainment Announce Acquisition, Strengthen Position as ‘Powerhouse’ in Entertainment Space

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, and its wholly owned subsidiary, Lavish Entertainment, have closed on the full acquisition of ABI Create, a premier event-management and production company. ABI Create was founded in 2015 by Lavish Entertainment president and COO Marco Antonio Moreno. Since its inception, ABI Create has established a reputation for delivering high-quality productions for a range of large-scale installations…

Tuesday Apr 09, 2024 - 9:29 am

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes on $3.2M Public Offering

Flora Growth (NASDAQ: FLGC), a cannabis-focused consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000-plus points of distribution around the world, has closed on an underwritten public offering. The offering, which was comprised of 1.7 million common shares, resulted in $3.23 million in gross proceeds for Flora Growth, before deductions. Flora Growth plans to use the funds from the…

Monday Apr 08, 2024 - 11:07 am

InvestorNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Approved as US Government Vendor, Proprietary TRACER 1000 Listed on GSA

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its wholly owned subsidiary, 1st Detect Corporation, have announced that its TRACER 1000(TM) is now listed in the U.S. General Services Administration (“GSA”) IT Schedule 70, making the company an approved U.S. government vendor. The device can be found under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290. According to the announcement, IT Schedule 70…

Thursday Apr 04, 2024 - 11:04 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting additional preclinical data demonstrating the positive effects of its INM-901 for the potential treatment of Alzheimer's disease ("AD"). Highlights of the report note that INM-901 receptor binding studies indicate preferential signaling agonism for both cannabinoid 1 (“CB1”) and cannabinoid 2 (“CB2”) and impacts the…

Thursday Apr 04, 2024 - 10:33 am

InvestorNewsBreaks – Golden Triangle Ventures Inc. (GTVH) to Release Series of CEO Interviews through Collaboration with NowMedia Networks

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, is partnering with NowMedia Networks to release a series of weekly interviews with GTVH CEO and president Steffan Dalsgaard. The series is initially planned for 12 weeks with the objective of sharing the company’s story. This partnership allows GTVH to distribute the interviews to more than 34 million televisions through 10-plus networks; these interviews will be…

Tuesday Apr 02, 2024 - 2:22 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives New Epilepsy, Anti-Viral Agent Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received three new patent awards. According to the announcement, the company was awarded two new patents in its epilepsy patent family; both awards were granted in the United States. The U.S. patents, which cover both swallowed capsules and dissolvable oral tablets, complement research indicating DehydraTECH-CBD has potential to decrease epileptic seizures in rodents…

Thursday Mar 28, 2024 - 2:38 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Capitalizing on ‘Overwhelming Interest’ to Focus on GLP-1 Applications of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM) technology for diabetes and weight loss for the 2024 calendar year. “This comes hot on the heels of a successful, active year of R&D in 2023, a year that saw significant strides in developing its patented DehydraTECH…

Friday Mar 08, 2024 - 2:33 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Subsidiary Tapping into Fast-Growing Opportunity

Astrotech (NASDAQ: ASTC), a science and technology company focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries, recently released financial results for Q2 2024. “The company recorded a 512% jump in its year-to-date (‘YTD’) revenue to $1,540,000 from $301,000 in the comparative period a year before. Astrotech attributed this growth primarily to two significant purchase orders for the TRACER 1000(TM)…

Friday Mar 01, 2024 - 3:21 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Breakthrough TRACER 1000(TM) Designed to Outperform Currently Used IMS Detectors

Astrotech (NASDAQ: ASTC) is a mass spectrometry company that, through its wholly owned subsidiary 1st Detect, has developed and rolled out the breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”). “The world’s first mass spectrometry-based ETD certified by the European Civil Aviation Conference (‘ECAC’), the TRACER 1000(TM) is designed to outperform the ETDs currently used at aviation checkpoints as well as borders, cargo facilities and other…

Wednesday Feb 21, 2024 - 3:11 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Subsidiary Bringing ‘Game Changer’ Technology in AgLAB MVP

Astrotech’s (NASDAQ: ASTC) subsidiary AgLAB, Inc. has breakthrough mass spectrometry technology in its AgLAB 1000-D2 mass spectrometer and the Maximum Value Process(TM) testing method (“AgLAB MVP”). “AgLAB MVP is designed to improve yields and bottom-line profits for hemp (‘CBD’) and cannabis (‘THC’) producers of CBD-THC oils by up to 30%. Large-scale CBD and THC oil processors use molecular distillation systems (‘MDS’) to produce the valuable…

Monday Feb 12, 2024 - 3:34 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 Drug to Bloodstream

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced the final results from its completed human Pilot Study #1 that sought to evaluate the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially in the branded product Rybelsus(R). “Most notable from its pilot study was the improved delivery of semaglutide to…

Wednesday Feb 07, 2024 - 1:01 pm

InvestorNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Introducing Breakthrough Technology, Potential ‘Game Changer’ for the Cannabinoid Industry

Astrotech (NASDAQ: ASTC) is an instrumentation company that is focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM). Its subsidiary, AgLAB Inc., has breakthrough mass spectrometry technology in its AgLAB-1000-D2 mass spectrometer, a ruggedized factory floor analytical instrument designed to quickly and easily analyze complex chemical compounds found in organic plant materials, and the Maximum Value Process(TM) testing method (“AgLAB MVP”). “AgLAB MVP is designed…

Friday Jan 26, 2024 - 2:25 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Pro-Control-1000(TM) Line Poised to Help Manufacturers Improve Profits, Yields

Astrotech (NASDAQ: ASTC ), an instrumentation company focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM) that is now used in airports and agriculture applications throughout the world, continues to expand its technology into new markets. “Astrotech has announced the introduction of its newest Pro-Control-1000(TM) product line of instrumentation designed to improve chemical manufacturing efficiencies. Astrotech is also announcing the creation of its newest wholly…

Friday Jan 12, 2024 - 2:07 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Grow Revenue and Commercial Opportunities Through Licensing

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is committed to providing healthier delivery methods of drugs and other active pharmaceutical ingredients (“APIs”) through its patented drug delivery technology, DehydraTECH(TM). “The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from…

Tuesday Dec 26, 2023 - 3:33 pm

InvestorNewsBreaks – Leveraging Commercial Viability of DehydraTECH(TM) in Aggressive Patent Application Push

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property (“IP”). “So far, Lexaria has received 37 granted patents globally, with many pending. The company is aggressively pushing its patent application process as it recognizes the viable commercial application of its flagship technology. In addition, the company understands that successfully granted patents can…

Friday Dec 15, 2023 - 3:23 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting New and More Lucrative Global Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is exploring the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for the treatment of diabetes and weight loss. “The move could help Lexaria carve out an important market share for an industry that is projected to bring in between $150 billion and $200 billion a year. Given…

Wednesday Nov 15, 2023 - 3:26 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Advance Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for a growing range of applications including oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. Through previous clinical trials, DehydraTECH-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks. “That we were able to lower blood pressure in our…

Friday Nov 03, 2023 - 2:53 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Proven Superior in Research

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track to submit an Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial HYPER H23-1. “Lexaria’s IND submission builds on five previous human clinical studies conducted from 2018 to 2022 and is integral to the successful filing and review of the submission. These studies were carried out in…

Friday Oct 20, 2023 - 3:29 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Committed to R&D, Eyeing Excellent Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform. The company continues to devote an increasing proportion of its resources and focus toward research and development (“R&D”) as part of its overall goal to establish areas of investigation for commercial pursuits and reduce risks of the unknown…

Monday Oct 02, 2023 - 2:39 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Nicotine Pouch Demonstrates Advantages over Competition

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported results from its human oral nicotine study NIC-H22-1, comparing Lexaria’s DehydraTECH(TM)-nicotine tobacco-free pouch to world-leading brands ZYN(R) and on! “Using measurements to determine the median time required to reach comparable nicotine concentrations within the bloodstream (‘Tmax’), Lexaria exhibited higher levels of certain pleasurable effects over the competition. DehydraTECH also provided the…

Friday Sep 15, 2023 - 2:50 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) New Subsidiary Maximizing Patented DehydraTECH(TM) in Various Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the incorporation of a new wholly owned subsidiary under the name Lexaria Nutraceutical Corp. (“LEXX Nutra”). “LEXX Nutra will keep with Lexaria’s overall strategy of maximizing the company’s patented DehydraTECH(TM) technology in various markets. Lexaria has issued an exclusive, perpetual license to LEXX Nutra, allowing the use of DehydraTECH to create…

Friday Sep 08, 2023 - 12:23 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) ‘Strategically Important’ Patent Grants Protection in One of World’s Leading Oral Nicotine Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently celebrated the receipt of U.S. patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine.” The patent covers various forms and sources of nicotine, including nicotine benzoate, nicotine polacrilex, nicotine citrate, nicotine detartrate, and many others, for use in sublingual delivery formats like oral pouches. “The new U.S. patent is remarkable…

Wednesday Aug 23, 2023 - 1:45 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Launching IND Program on DehydraTECH-CBD for Hypertension

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been published in eight peer-reviewed articles across six different publications. “The most recent publication in June 2023 in the peer-reviewed International Journal of Molecular Sciences is ‘Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study.’…

Friday Jul 14, 2023 - 2:22 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Study Reveals ‘Most Convincing Evidence’ of CBD’s Anti-Inflammatory Actions in Humans

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced additional findings from its human clinical study HYPER-H21-4, completed last year. “The hypertension study sought to evaluate DehydraTECH-processed cannabidiol (“CBD”) as a potential antihypertensive medication and already achieved primary efficacy and safety objectives. According to the company, the study also demonstrated significant reductions in several pro-inflammatory biomarkers – interleukin (‘IL’) 8, 10 and 18 – known to be…

Monday Jul 03, 2023 - 12:09 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen Hormone than Control

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol. “The study found that the DehydraTECH-estradiol composition resulted in a maximum concentration in the bloodstream (‘Cmax’) of 5.65 ng/mL, which was approximately 900% higher than the control formulation’s…

Monday Jun 12, 2023 - 12:55 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Experienced Financial Professional as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of a new chief financial officer. Effective immediately, Mike Shankman will serve as outsourced CFO. An experienced accounting and finance professional, Shankman has held senior positions with companies in the biotechnology, medical devices and software-as-a-service industries. As a consultant with NOW CFO, one of his current clients is a…

Friday Jun 09, 2023 - 10:39 am

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio of Worldwide Patents

Lexaria Bioscience Corp. (NASDAQ: LEXX), the global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs through its patented DehydraTECH(TM) technology, recently announced it had received notification of four newly awarded or allowed patents. “The new patents will add to Lexaria’s growing portfolio and, upon award, will bring the total number of patents granted worldwide to 32, with several…

Monday Apr 17, 2023 - 1:22 pm

InvestorNewsBreaks – Prime Harvest Inc. Eyes Continued Growth and Expansion with Recently Launched Reg A+ Offering

Prime Harvest, a tech-focused legal cannabis enterprise and parent company to SoCal’s premier dispensary JAXX Cannabis, recently launched Weed 4 The People – the company’s Reg A+ offering that allows the public to own a piece of the company for as little as $4.20 per share at a minimum of 100 shares. “Prime Harvest aims to raise upwards of $42M to fund the expansion of…

Friday Apr 14, 2023 - 12:52 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Positive Results in First Diabetes Study

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability of and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM). “Most recently, a company announcement indicates that a just-completed DIAB-A22-1 diabetes study has produced at least three positive outcomes, including weight loss in obese diabetic-conditioned animals…

Monday Apr 03, 2023 - 3:18 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Foundation for Improving Effectiveness of Lipophilic Drugs, APIs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is positioned for opportunity with its patented DehydraTECH(TM) technology and its wide-reaching potential. “Lexaria’s DehydraTECH is designed to formulate and deliver lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (‘APIs’). DehydraTECH increases the effectiveness of and improves the way APIs enter the bloodstream. The benefits of consuming a DehydraTECH-enabled drug or product include: speed…

Friday Mar 24, 2023 - 12:34 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Efforts to Boost Commercial Prospects ‘Paying off in Spades’

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology. Lexaria is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its technology for both consumer and pharmaceutical sectors. “The materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that…

Friday Mar 17, 2023 - 1:29 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moving Closer to Providing Alternative Hypertension Treatment with DehydraTECH(TM)-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported additional findings from its most comprehensive clinical study yet, HYPER-H21-4. “The findings showed that DehydraTECH-CBD resulted in a statistically significant reduction in average baseline serum catestatin concentrations of 13.50 ng/mL to just 9.65 ng/mL after five weeks of dosing, representing a 28.5% drop. In addition, mean arterial pressure significantly dropped by…

Monday Mar 13, 2023 - 2:47 pm

InvestorNewsBreaks – Prime Harvest Inc. Secures Reg A+ Qualification, Eyes New Heights of Opportunity

Prime Harvest, a technology focused, full-service cannabis company, recently announced that its Regulation A+ offering, which seeks to raise up to $42 million, had been qualified by the U.S. Securities and Exchange Commission (“SEC”). “The company has announced that gross proceeds from the equity raising will be destined towards the acquisition of licensed assets, the development of Prime Harvest’s direct-to-consumer application, expansion of the company’s…

InvestorNewsBreaks

NewsBreak Category: Hemp

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions